This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spitzer TR . Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893–898.
Imahashi N, Inamoto Y, Ito M, Koyama D, Goto T, Onodera K et al. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47: 387–394.
Abe Y, Choi I, Hara K, Matsushima T, Nishimura J, Inaba S et al. Hemophagocytic syndrome: a rare complication of allogeneic nonmyeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 799–801.
Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant 2005; 11: 542–550.
Schmid I, Stachel D, Pagel P, Albert MH . Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2008; 14: 438–444.
Nishio N, Yagasaki H, Takahashi Y, Hama A, Muramatsu H, Tanaka M et al. Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. Pediatr Transplant 2009; 13: 831–837.
Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H et al. Peri-engraftment syndrome in allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48: 523–528.
Chang L, Frame D, Braun T, Gatza E, Hanauer DA, Zhao S et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant 2014; 20: 1407–1417.
Kanda J, Kaynar L, Kanda Y, Prasad VK, Parikh SH, Lan L et al. Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transplant 2013; 48: 926–931.
Nishiwaki S, Nakayama T, Murata M, Nishida T, Terakura S, Saito S et al. Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. PLoS ONE 2014; 9: e96252.
Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S et al. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol 2012; 95: 428–433.
Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728.
Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M . Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012; 18: 1727–1733.
Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462–2468.
Acknowledgements
We wish to thank all of the staff who contributed to patient care at our institute. This study was partially supported by a grant from the National Center for Child Health and Development (grant number 26-14), Tokyo, Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Sakaguchi, H., Matsumoto, K., Yoshida, N. et al. Dexamethasone palmitate for patients with engraftment syndrome is associated with favorable outcome for children with hematological malignancy. Bone Marrow Transplant 51, 1540–1542 (2016). https://doi.org/10.1038/bmt.2016.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.178
This article is cited by
-
Dexamethasone palmitate as an etoposide-free treatment for children with hemophagocytic lymphohistiocytosis after hematopoietic cell transplantation
Bone Marrow Transplantation (2023)
-
Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome
International Journal of Hematology (2019)